How to Reconstitute GLP-2/Tirz: A Step-by-Step Guide
Reconstituting GLP-2/Tirz is not identical to reconstituting any other compound in this library. Dissolves well but shares the amphiphilic behaviour of all lipidated peptides — prone to foaming, self-associating at higher concentrations.
Overview
Add liquid down the vial wall and give it several minutes of gentle swirling. Slow dissolving is normal for this molecule, not a sign of a bad vial. A 10 mg vial in 2 mL gives 5 mg/mL. Do not try to hurry it along by shaking.
What GLP-2/Tirz actually is
GLP-2/Tirz is an engineered molecule acting on two receptors in the gut-hormone system involved in blood-sugar regulation. It carries a design detail that is very widely misreported: it was built on a GIP backbone and then modified to also engage GLP-1, whereas most compounds in its class went the other way round.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
Diluent selection for GLP-2/Tirz
Dissolves well but shares the amphiphilic behaviour of all lipidated peptides — prone to foaming, self-associating at higher concentrations. Allow several minutes of gentle swirling rather than forcing dissolution.
Common reconstitution reference
A 10 mg vial in 2 mL yields 5 mg/mL. Allow several minutes for full dissolution without agitation.
Open the GLP-2/Tirz calculatorMethod notes for this compound
- Swirl, never shake or vortex.
- Add diluent down the vial wall and give the cake time — several minutes of slow dissolution is normal, not a defect.
- Store upright and refrigerated; do not freeze once reconstituted.
What GLP-2/Tirz is studied for
Simultaneous GIP and GLP-1 receptor activity from a GIP-derived backbone.
Core metabolic research endpoints for the incretin class.
A well-characterised GLP-1 pathway effect studied in metabolic models.
Whether GIP agonism or antagonism is the productive direction remains an active research debate.
Summarizes published preclinical literature — see the selected references below. Provided for research reference only; not a claim of efficacy or a description of human use.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. GLP-2/Tirz Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
- Browse current GLP-2/Tirz literature on PubMed
References describe in-vitro and preclinical research and are listed for reference only — not evidence of efficacy and not a description of human use.
More GLP-2/Tirz reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Which solvents work, why, and what abnormal dissolution behaviour indicates.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Which assays are informative for this molecule, and what to actually check on its COA.
Compound-specific bench practices, and the errors most often made with this molecule.
What to inspect on arrival, and which conditions actually warrant rejecting a vial.
Questions specific to this compound — structure, chemistry, and common misconceptions.
Reconstitution reference for other compounds
Reviewed for research-use compliance by Kobi Williams, Founder — Popular Peptides Canada. Last reviewed 22 July 2026.
GLP-2/Tirz is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.